This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: University of California. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: The Innovative Contributions of Benjamin Kellman
Introduction
Benjamin Kellman is an accomplished inventor based in La Jolla, California. He has made significant strides in the field of antiviral therapeutics. His work focuses on the application of microbial glycosidase, which has the potential to revolutionize the way viral infections are diagnosed and treated.
Latest Patents
Kellman holds a patent for the "Application of microbial glycosidase as an anti-viral therapeutic, prognostic, and diagnostic." This patent outlines methods and compositions for diagnosing, preventing, or treating viral infections. It specifically involves administering an effective amount of a glycosidase or a sulfatase to degrade glycans, such as heparan sulfate, to inhibit viral infections, including COVID-19. The patent also details methods for identifying glycosidases, sulfatases, or microbes associated with increased susceptibility to viral infections.
Career Highlights
Kellman is affiliated with the University of California, where he conducts research and develops innovative solutions in the field of virology. His work has garnered attention for its potential impact on public health, particularly in the context of emerging viral threats.
Collaborations
Kellman collaborates with various professionals in his field, including his coworker Cameron Martino. Their combined expertise contributes to the advancement of research in antiviral therapies.
Conclusion
Benjamin Kellman's innovative work in the application of microbial glycosidase represents a significant advancement in the fight against viral infections. His contributions have the potential to improve diagnostic and therapeutic strategies, ultimately benefiting public health.